Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis.
Brandon K MartinezJit ShethNishi PatelWilliam L BakerCraig I ColemanPublished in: Pharmacotherapy (2018)
This meta-analysis suggests that incidences of recurrent VTE and major bleeding among rivaroxaban-managed patients are not dissimilar to those seen in recent randomized trials of anticoagulation in CAT. The pooled incidence for mortality was lower than reported in many anticoagulation CAT trials. This may suggest that rivaroxaban is being used in CAT patients who have less severe cancer.
Keyphrases
- venous thromboembolism
- atrial fibrillation
- end stage renal disease
- systematic review
- ejection fraction
- chronic kidney disease
- newly diagnosed
- pulmonary embolism
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- squamous cell carcinoma
- type diabetes
- cardiovascular events
- papillary thyroid
- squamous cell
- lymph node metastasis
- double blind